Story perspectives

Leqvio Outperforms Statins: 85% Achieve Cholesterol Goals

8/31/2025

50 12

Summary

Story summary

Leqvio, a cholesterol-lowering injection by Novartis, helps patients reach cholesterol goals more quickly than statins.
In the V-DIFFERENCE trial, 85% of Leqvio patients achieved targets, versus 31% in the placebo group.
Leqvio patients reported 43% less muscle pain compared to those on placebo.
The NHS Health Survey found elevated cholesterol levels in 53% of adults in 2022, up from 43% in 2019.
Trial results will be presented at the European Society of Cardiology Congress in Madrid.

1 of 1

Story summary

Leqvio, a cholesterol-lowering injection by Novartis, helps patients reach cholesterol goals more quickly than statins.
In the V-DIFFERENCE trial, 85% of Leqvio patients achieved targets, versus 31% in the placebo group.
Leqvio patients reported 43% less muscle pain compared to those on placebo.
The NHS Health Survey found elevated cholesterol levels in 53% of adults in 2022, up from 43% in 2019.
Trial results will be presented at the European Society of Cardiology Congress in Madrid.